132 related articles for article (PubMed ID: 28131549)
1. Cortactin and phosphorylated cortactin tyr
Marioni G; Zanoletti E; Mazzoni A; Gianatti A; Valentini E; Girasoli L; Guariento M; Giacomelli L; Martini A; Blandamura S
Am J Otolaryngol; 2017; 38(2):208-212. PubMed ID: 28131549
[TBL] [Abstract][Full Text] [Related]
2. Relaxin-2 expression in temporal bone carcinoma.
Marioni G; Zanoletti E; Lovato A; Franchella S; Giacomelli L; Gianatti A; Mazzoni A; Blandamura S; Martini A
Eur Arch Otorhinolaryngol; 2015 Nov; 272(11):3225-32. PubMed ID: 25388992
[TBL] [Abstract][Full Text] [Related]
3. Temporal bone squamous cell carcinoma: analyzing prognosis with univariate and multivariate models.
Zanoletti E; Marioni G; Stritoni P; Lionello M; Giacomelli L; Martini A; Mazzoni A
Laryngoscope; 2014 May; 124(5):1192-8. PubMed ID: 24108656
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the prognostic role of pSTAT3 expression in temporal bone squamous cell carcinoma.
Marioni G; Nucci R; Marino F; Cappellesso R; Pillon M; Zanoletti E; Giacomelli L; Franchella S; Billo P; Pareschi R; Martini A
Otol Neurotol; 2013 Oct; 34(8):1476-82. PubMed ID: 24005169
[TBL] [Abstract][Full Text] [Related]
5. Temporal bone carcinoma: a first glance beyond the conventional clinical and pathological prognostic factors.
Marioni G; Martini A; Favaretto N; Franchella S; Cappellesso R; Marino F; Blandamura S; Mazzoni A; Zanoletti E
Eur Arch Otorhinolaryngol; 2016 Oct; 273(10):2903-10. PubMed ID: 26518208
[TBL] [Abstract][Full Text] [Related]
6. Guidelines for treating temporal bone carcinoma based on long-term outcomes.
Bacciu A; Clemente IA; Piccirillo E; Ferrari S; Sanna M
Otol Neurotol; 2013 Jul; 34(5):898-907. PubMed ID: 23507994
[TBL] [Abstract][Full Text] [Related]
7. Recurrent squamous cell carcinoma of the temporal bone: critical analysis of cases with a poor prognosis.
Zanoletti E; Marioni G; Franchella S; Lovato A; Giacomelli L; Martini A; Mazzoni A
Am J Otolaryngol; 2015; 36(3):352-5. PubMed ID: 25595048
[TBL] [Abstract][Full Text] [Related]
8. Cortactin and phosphorylated cortactin tyr
Marioni G; Lionello M; Marchese-Ragona R; Fasanaro E; Valentini E; Zanoletti E; Stritoni P; Ramacciotti G; Guzzardo V; Giacomelli L; Ralli G; Ottaviano G; Blandamura S
Int J Biol Markers; 2018 Jan; 33(1):79-86. PubMed ID: 28885660
[TBL] [Abstract][Full Text] [Related]
9. Tumor budding to investigate local invasion, metastasis and prognosis in temporal bone squamous cell carcinoma.
Alessandrini L; Zanoletti E; Cazzador D; Sbaraglia M; Franz L; Tealdo G; Frigo AC; Blandamura S; Nicolai P; Mazzoni A; Marioni G
Pathol Res Pract; 2022 Jan; 229():153719. PubMed ID: 34953406
[TBL] [Abstract][Full Text] [Related]
10. Clinical and pathological parameters prognostic for increased risk of recurrence after postoperative radiotherapy for temporal bone carcinoma.
Marioni G; Zanoletti E; Giacomelli L; Braggio L; Martini A; Mazzoni A
Head Neck; 2016 Jun; 38(6):894-8. PubMed ID: 26348213
[TBL] [Abstract][Full Text] [Related]
11. Management of squamous cell carcinoma of the temporal bone: long-term results and factors influencing outcomes.
Piras G; Grinblat G; Albertini R; Sykopetrites V; Zhong SX; Lauda L; Sanna M
Eur Arch Otorhinolaryngol; 2021 Sep; 278(9):3193-3202. PubMed ID: 32979119
[TBL] [Abstract][Full Text] [Related]
12. Neoangiogenesis in temporal bone carcinoma: the prognostic role of CD105.
Marioni G; Nucci R; Marino F; Giacomelli L; Rugge M; Pareschi R; Martini A
Otol Neurotol; 2012 Jul; 33(5):843-8. PubMed ID: 22643443
[TBL] [Abstract][Full Text] [Related]
13. Cortactin overexpression in the esophageal squamous cell carcinoma and its involvement in the carcinogenesis.
Hsu NY; Yeh KT; Chiang IP; Pai LY; Chen CY; Ho HC
Dis Esophagus; 2008; 21(5):402-8. PubMed ID: 19125793
[TBL] [Abstract][Full Text] [Related]
14. Expression of the tumour-suppressor maspin in temporal bone carcinoma.
Marioni G; Zanoletti E; Stritoni P; Lionello M; Giacomelli L; Gianatti A; Cattaneo L; Blandamura S; Mazzoni A; Martini A
Histopathology; 2013 Aug; 63(2):242-9. PubMed ID: 23730906
[TBL] [Abstract][Full Text] [Related]
15. Distinctive clinicopathological associations of amplification of the cortactin gene at 11q13 in head and neck squamous cell carcinomas.
Rodrigo JP; García-Carracedo D; García LA; Menéndez S; Allonca E; González MV; Fresno MF; Suárez C; García-Pedrero JM
J Pathol; 2009 Mar; 217(4):516-23. PubMed ID: 18991334
[TBL] [Abstract][Full Text] [Related]
16. Temporal bone carcinoma: testing the prognostic value of a novel clinical and histological scoring system.
Franz L; Zanoletti E; Franchella S; Cazzador D; Favaretto N; Calvanese L; Mazzoni A; Nicolai P; Marioni G
Eur Arch Otorhinolaryngol; 2021 Nov; 278(11):4179-4186. PubMed ID: 33231758
[TBL] [Abstract][Full Text] [Related]
17. A critical look at persistent problems in the diagnosis, staging and treatment of temporal bone carcinoma.
Zanoletti E; Lovato A; Stritoni P; Martini A; Mazzoni A; Marioni G
Cancer Treat Rev; 2015 Dec; 41(10):821-6. PubMed ID: 26549119
[TBL] [Abstract][Full Text] [Related]
18. Pathologic significance and prognostic value of phosphorylated cortactin expression in patients with sarcomatoid renal cell carcinoma.
Matsuo T; Miyata Y; Watanabe S; Ohba K; Hayashi T; Kanda S; Sakai H
Urology; 2011 Aug; 78(2):476.e9-15. PubMed ID: 21696810
[TBL] [Abstract][Full Text] [Related]
19. Temporal bone squamous cell carcinoma: A change in treatment.
Ngu CYV; Mohd Saad MS; Tang IP
Med J Malaysia; 2021 Sep; 76(5):725-730. PubMed ID: 34508382
[TBL] [Abstract][Full Text] [Related]
20. Cortactin, fascin, and survivin expression associated with clinicopathological parameters in esophageal squamous cell carcinoma.
Hsu KF; Lin CK; Yu CP; Tzao C; Lee SC; Lee YY; Tsai WC; Jin JS
Dis Esophagus; 2009; 22(5):402-8. PubMed ID: 19207554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
